On January 6, 2023, the FDA granted lecanemab-irmb (Leqembi) accelerated approval for treating mild cognitive impairment and mild dementia in patients with Alzheimer disease.
Kevin Chamberlain, PharmD, FASCP
Advertisement
Articles by Kevin Chamberlain, PharmD, FASCP
Overall median survival was higher in participants taking quizartinib, according to results from QuANTUM-First trial.
Mavacamten improves functional capacity and symptoms in adults with New York Heart Association class II-III obstructive HCM.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Drug Topics
1
The Drug Price Paradox: PBMs, Pharmacies, and the Path to Affordability
2
Zepbound Lowers Health Care Costs in Older Adults With Obesity
3
How mRNA and Protein-Based COVID-19 Vaccines Work
4
Updated Guideline Refines Approach to Migraine Prevention in Adults
5